




# New Systemic Options for Managing cSCC

A Care Team Forum<sup>SM</sup>

*Part 1*

# Surgical Efficacy

## 5-Year Cure Rate BY PROCEDURE TYPE



# Mohs Surgery

## Advantages

---



Tissue sparing



Allows for histological examination of 100% of surgical margins



Minimally disfiguring



Good for particularly aggressive tumors

## Disadvantages

---



Time consuming



Technique dependent

# Ineligible for Surgery?



## PROCEDURAL LOGISTICS

Can the patient tolerate the procedure?  
Can s/he lay or sit still for 30 to 45 minutes?  
Is the patient capable of wound care?



## CONFIDENCE

Is there low confidence in obtaining clear margins?



## LOCATION


Is the tumor large or deep such that surgery will lead to significant morbidity (eg, vision loss)?



## SPREAD


Has the tumor spread beyond the primary site to draining lymph node base or distant organs?

# Mechanism: PD-1 Inhibition




# Phase 2: Best Tumor Response


Tumor Response over Time for 28 Patients in the Phase 2 Study



# Phase 2: Best Tumor Response




# Progression-free Survival





# Cemiplimab: Safety



# Managing irAEs

VOLUME 36 · NUMBER 17 · JUNE 10, 2018

JOURNAL OF CLINICAL ONCOLOGY

A S C O S P E C I A L A R T I C L E

## Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

*Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura D. Porter, Igor Puzanov, Cristina A. Reichner, Bianca D. Santomaso, Carole Seigel, Alexander Spira, Maria E. Suarez-Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, and John A. Thompson in collaboration with the National Comprehensive Cancer Network*



*Stay Tuned for...*

# *Selecting the RIGHT Patient for Systemic Therapy in cSCC*

A Care Team Forum<sup>SM</sup>

*Part II*